Alpha Tau Medical Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K covers the month of April 2026, with the report dated April 23, 2026. Alpha Tau Medical Ltd., a foreign private issuer based in Jerusalem, Israel, filed this report to disclose two significant clinical trial developments regarding its Alpha DaRT® technology.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial milestones and regulatory approvals rather than financial performance.
Material Changes and Developments
- ACAPELLA Clinical Trial: The Company successfully treated its first pancreatic cancer patient in Europe using Alpha DaRT® within the French multicenter ACAPELLA clinical trial.
- IMPACT Clinical Trial: The Company received FDA approval for an Investigational Device Exemption (IDE) supplement. This approval expands the Alpha DaRT® IMPACT trial to include patients with pancreatic cancer receiving Gemcitabine with Abraxane® (Nab-Paclitaxel).
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future earnings, or a detailed discussion of risks and contingencies beyond the standard legal disclaimer. The outlook is implied through the progression of clinical trials and regulatory approvals.
Investor Verification Checklist
- Verify the full text of the press releases attached as Exhibit 99.1 (ACAPELLA) and Exhibit 99.2 (IMPACT) for detailed trial protocols and patient eligibility criteria.
- Confirm the timeline for subsequent patient enrollments in the ACAPELLA and IMPACT trials.
- Review the Company's most recent Form 20-F or quarterly reports for current cash runway and burn rate, as this 6-K does not disclose financial status.
- Monitor future regulatory communications regarding the scope of the FDA-approved IDE supplement.